

	Pfizer/BioNTech	Moderna	J and J
Name	Comirnaty (BNT162b2)	mRNA-1273	Ad26.COV2.S
Vaccine Type	mRNA	mRNA	Adenovirus Vector
Primary Series	2 dose (30ug/0.3 ml) 21 days apart	2 dose (100 ug/0.5 ml) 30 days apart	1 dose (0.5ml)
3rd Dose	Use of an additional dose for persons aged ≥ 12 years at or after 28 days from an initial 2-dose primary vaccine series for moderately to severely immunocompromised people.	Use of an additional dose for persons aged ≥ 18 years at or after 28 days from an initial 2-dose primary vaccine series for moderately to severely immunocompromised people.	No FDA recommendations yet
Booster doses	FDA EUA approval. 30ug single dose @ least 6 months after a <i>Pfizer-BioNTech primary series</i> (2 doses). CDC guidance for use is below.	No FDA recommendations yet	No FDA recommendations yet
Booster dose is <u>recommended</u> for:	People <i>65 years and older, residents in long-term care settings</i> or people aged <i>50–64 years with underlying medical conditions</i>	No FDA recommendations yet	No FDA recommendations yet
Booster dose <u>may</u> be given to:	People aged <i>18–49 years with underlying medical conditions</i> or people aged <i>18–64 years who are at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting</i>	No FDA recommendations yet	No FDA recommendations yet